{"id":303,"date":"2026-02-18T16:12:56","date_gmt":"2026-02-18T14:12:56","guid":{"rendered":"http:\/\/example.test\/?post_type=product&#038;p=303"},"modified":"2026-07-21T11:13:40","modified_gmt":"2026-07-21T08:13:40","slug":"semaglutide-10-mg","status":"publish","type":"product","link":"https:\/\/life-peptide.com\/es\/product\/semaglutide-10-mg\/","title":{"rendered":"Semaglutide 10 mg"},"content":{"rendered":"<p>Semaglutide is a <strong>long-acting GLP-1 receptor agonist<\/strong> engineered to mimic the activity of endogenous glucagon-like peptide-1 while providing substantially longer biological activity than the native hormone.\u00a0Unlike <a href=\"https:\/\/life-peptide.com\/es\/product\/tirzepatide-10-mg\/\">Tirzepatida<\/a> y <a href=\"https:\/\/life-peptide.com\/es\/product\/retatrutide-10-mg\/\">Retatrutida<\/a>, Semaglutide activates only the GLP-1 receptor, making it the simplest member of the current generation of incretin peptides. This selective mechanism has made Semaglutide <strong>one of the most extensively investigated metabolic peptides<\/strong> in both preclinical and clinical research over the past decade.<\/p>\n<p>Because of this large body of evidence, Semaglutide is frequently used as <strong>the reference compound<\/strong> when evaluating newer dual- and triple-receptor agonists.<\/p>\n<h4><strong>Why Semaglutide remains important in metabolic research<\/strong><\/h4>\n<p>Although newer multi-receptor agonists have attracted considerable attention, Semaglutide continues to serve as the scientific benchmark for GLP-1 biology.<\/p>\n<p>Published research has investigated Semaglutide in relation to:<\/p>\n<ul>\n<li><strong>appetite regulation<\/strong><\/li>\n<li><strong>body-weight reduction<\/strong><\/li>\n<li><strong>glycaemic control<\/strong><\/li>\n<li><strong>insulin secretion<\/strong><\/li>\n<li><strong>gastric emptying<\/strong><\/li>\n<li><strong>cardiovascular outcomes<\/strong><\/li>\n<li><strong>metabolic syndrome<\/strong><\/li>\n<li><strong>non-alcoholic fatty liver disease<\/strong><\/li>\n<li><strong>long-term incretin signalling<\/strong><\/li>\n<\/ul>\n<p>Its extensive clinical literature makes Semaglutide one of the most important comparator molecules in obesity and metabolic research. Many modern studies evaluating Tirzepatide, Retatrutide and emerging GLP-1 combinations use Semaglutide as <strong>the reference standard<\/strong>.<\/p>\n<h4><strong>How Semaglutide works<\/strong><\/h4>\n<p>Semaglutida <strong>selectively activates the GLP-1 receptor<\/strong>, a key regulator of appetite, glucose homeostasis and gastrointestinal signalling.<\/p>\n<p>Activation of GLP-1 receptors has been associated in published research with:<\/p>\n<ul>\n<li>glucose-dependent insulin secretion<\/li>\n<li>suppression of glucagon release<\/li>\n<li>delayed gastric emptying<\/li>\n<li>reduced food intake<\/li>\n<li>altered central appetite signalling<\/li>\n<li>improvements in several metabolic markers<\/li>\n<\/ul>\n<p>Unlike Tirzepatide, Semaglutide does <strong>no<\/strong> activate GIP receptors.\u00a0Unlike Retatrutide, it has <strong>no glucagon<\/strong> receptor activity.<\/p>\n<p>Its value therefore lies in providing a well-characterised <strong>single-pathway GLP-1 model<\/strong>, making it the logical comparator for newer incretin compounds.<\/p>\n<h4><strong>Published clinical findings on Semaglutide<\/strong><\/h4>\n<p>Semaglutide has one of <strong>the largest human evidence<\/strong> bases of any peptide currently used in metabolic research.<\/p>\n<p>In the STEP clinical programme, once-weekly Semaglutide produced <strong>substantial reductions in body weight<\/strong> over 68-week treatment periods, establishing GLP-1 receptor agonism as a major therapeutic strategy for obesity research.<\/p>\n<p>Beyond weight-related outcomes, multiple large clinical programmes have demonstrated improvements in:<\/p>\n<ul>\n<li>HbA1c<\/li>\n<li>fasting glucose<\/li>\n<li>waist circumference<\/li>\n<li>blood pressure<\/li>\n<li>selected cardiovascular outcomes<\/li>\n<li>cardiometabolic risk markers<\/li>\n<\/ul>\n<p>Because these findings have been reproduced across numerous independent trials, Semaglutide remains <strong>the principal benchmark<\/strong> against which newer dual- and triple-agonist peptides are evaluated.<\/p>\n<h4><strong>Resultados publicados de seguridad y tolerabilidad<\/strong><\/h4>\n<p>Published clinical studies consistently identify gastrointestinal events as the most common adverse effects associated with Semaglutide.\u00a0Frequently reported events include: nausea,\u00a0vomiting, diarrhoea, constipation and abdominal discomfort.<\/p>\n<p>Across the major clinical programmes, these events were generally most pronounced during <strong>dose escalation<\/strong> and were typically described as <strong>leve a moderado<\/strong> in severity. As with other GLP-1 receptor agonists, gradual dose escalation was an important component of the published research protocols used to improve tolerability.<\/p>\n<p>This section summarises published findings on investigational and clinical Semaglutide research and is not intended as guidance for use of this product.<\/p>\n<h4><strong>Published dosing schedules used in Semaglutide research<\/strong><\/h4>\n<p>Published Semaglutide studies generally employed once-weekly administration with gradual dose escalation, allowing investigators to evaluate both efficacy and gastrointestinal tolerability over extended treatment periods.<\/p>\n<p>Across the major obesity and diabetes programmes, <strong>escalation protocols<\/strong> were used before reaching maintenance doses, with studies continuing for up to 68 weeks in obesity research. The published literature therefore reflects structured clinical trial design rather than a single universal dosing schedule.<\/p>\n<table style=\"height: 174px;\" width=\"698\">\n<thead>\n<tr>\n<td><strong>Published study context<\/strong><\/td>\n<td><strong>Study design<\/strong><\/td>\n<td><strong>Frecuencia<\/strong><\/td>\n<td><strong>Duration<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>STEP obesity programme<\/td>\n<td>gradual dose escalation<\/td>\n<td>una vez por semana<\/td>\n<td>68 weeks<\/td>\n<\/tr>\n<tr>\n<td>SUSTAIN diabetes programme<\/td>\n<td>gradual dose escalation<\/td>\n<td>una vez por semana<\/td>\n<td>varied<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>These schedules summarise published clinical research design and are not instructions for use of this product.<\/p>\n<h4><strong>Semaglutide vs Tirzepatide vs Retatrutide<\/strong><\/h4>\n<p><strong>Semaglutida<\/strong><\/p>\n<ul>\n<li>GLP-1 receptor agonist<\/li>\n<li><strong>single<\/strong> receptor mechanism<\/li>\n<li>largest clinical evidence base<\/li>\n<li>reference compound for GLP-1 research<\/li>\n<\/ul>\n<p><strong>Tirzepatida<\/strong><\/p>\n<ul>\n<li>GLP-1 + GIP <strong>dual<\/strong> agonist<\/li>\n<li>broader incretin signalling<\/li>\n<li>frequently compared directly with Semaglutide<\/li>\n<\/ul>\n<p><strong>Retatrutida<\/strong><\/p>\n<ul>\n<li>GLP-1 + GIP + glucagon <strong>triple<\/strong> agonist<\/li>\n<li>broadest receptor profile<\/li>\n<li>represents the newest generation of multi-receptor metabolic peptides<\/li>\n<\/ul>\n<p>For researchers investigating incretin biology, Semaglutide provides the foundation from which dual- and triple-agonist compounds can be evaluated.<\/p>\n<h4><strong>Caracter\u00edsticas del producto<\/strong><\/h4>\n<p>Aplicaci\u00f3n: investigaci\u00f3n de laboratorio y an\u00e1lisis<br \/>\nUso restringido: no apto para consumo humano; no apto para uso m\u00e9dico, veterinario o cosm\u00e9tico<br \/>\nProducido en instalaciones que cumplen con GMP bajo estrictos protocolos de control de calidad.<br \/>\nCada lote se somete a pruebas de laboratorio exhaustivas despu\u00e9s de la producci\u00f3n (puede encontrar el Certificado de An\u00e1lisis debajo de las im\u00e1genes del producto).<br \/>\nLiofilizado (liofilizado) para m\u00e1xima estabilidad y vida \u00fatil prolongada.<br \/>\nSellado en viales est\u00e9riles, listo para la reconstituci\u00f3n.<br \/>\nPurity: \u226599% (HPLC-tested)<br \/>\nAppearance: Lyophilized white\/off-white powder<br \/>\nF\u00f3rmula molecular: C<sub>187<\/sub>H<sub>291<\/sub>N<sub>45<\/sub>O<sub>59<\/sub><br \/>\nMolecular weight: 4113.64<br \/>\nSequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-\u03b3-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly<br \/>\n<strong>Almacenamiento<\/strong>: los viales liofilizados sin abrir se almacenan mejor <strong>refrigerar a 2\u20138 \u00b0C<\/strong>, que es el m\u00e9todo de almacenamiento confirmado por nuestro socio de fabricaci\u00f3n y adecuado para hasta 24 meses. Se prefiere la refrigeraci\u00f3n porque minimiza los ciclos innecesarios de congelaci\u00f3n y descongelaci\u00f3n durante la manipulaci\u00f3n rutinaria. Si se requiere un almacenamiento a m\u00e1s largo plazo, los viales liofilizados sin abrir tambi\u00e9n pueden mantenerse congelados. Una vez reconstituidos, almacene siempre a 2\u20138 \u00b0C y no congele.<\/p>\n<h4><strong>Reconstituci\u00f3n y manipulaci\u00f3n<\/strong><\/h4>\n<p>Semaglutide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with <a href=\"https:\/\/life-peptide.com\/es\/product\/bac-10-ml\/\">agua bacteriost\u00e1tica<\/a> Antes de usar. Los p\u00e9ptidos de la clase GLP-1 a veces tardan en disolverse y requieren una reconstituci\u00f3n muy suave para evitar la formaci\u00f3n de espuma o que queden ligeramente turbios.<\/p>\n<p>Para otras gu\u00edas sobre selecci\u00f3n de solventes, planificaci\u00f3n de concentraciones y almacenamiento, consulte el completo <a href=\"https:\/\/life-peptide.com\/es\/reconstitution-of-peptides\/\">Gu\u00eda de Reconstituci\u00f3n de P\u00e9ptidos<\/a> y <a href=\"https:\/\/life-peptide.com\/es\/calculator\/\">Calculadora de Reconstituci\u00f3n<\/a>.<\/p>\n<h4>Estudios clave publicados<\/h4>\n<ul>\n<li>Wilding JPH et al. \u201c<em>Once-Weekly Semaglutide in Adults with Overweight or Obesity.\u201d New England Journal of Medicine<\/em>, 2021.<\/li>\n<li>Frias JP, Davies MJ, Rosenstock J, et al.\u00a0<em>Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine<\/em>. 2021.<\/li>\n<li>Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.\u00a0<em>Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine<\/em>. 2023.<\/li>\n<li>Aroda VR.\u00a0<em>A Review of the SUSTAIN Clinical Trial Programme. Diabetes, Obesity and Metabolism<\/em>. 2019.<\/li>\n<\/ul>\n<h4><strong>Preguntas frecuentes<\/strong><\/h4>\n<p><strong>What is Semaglutide?<\/strong><\/p>\n<p>Semaglutide is a long-acting GLP-1 receptor agonist that mimics the activity of the naturally occurring incretin hormone glucagon-like peptide-1. It has become one of the most extensively studied metabolic peptides and serves as the reference compound for modern GLP-1 research. Published studies have investigated Semaglutide in relation to appetite regulation, glucose homeostasis, body-weight outcomes and broader cardiometabolic signalling.<\/p>\n<p><strong>How does Semaglutide work?<\/strong><\/p>\n<p>Semaglutide selectively activates the GLP-1 receptor, a pathway involved in regulating insulin secretion, glucagon release, gastric emptying and appetite signalling. Unlike newer dual- and triple-receptor agonists, it acts only on GLP-1 receptors, making it an important reference molecule for researchers comparing different incretin-based therapeutic strategies.<\/p>\n<p><strong>How is Semaglutide different from Tirzepatide?<\/strong><\/p>\n<p>Semaglutide activates only the GLP-1 receptor, whereas Tirzepatide is a dual GLP-1\/GIP agonist. Both compounds belong to the incretin class, but Tirzepatide expands the mechanism beyond GLP-1 signalling. As a result, Semaglutide is often used as the benchmark against which dual agonists are evaluated in metabolic research.<\/p>\n<p><strong>How is Semaglutide different from Retatrutide?<\/strong><\/p>\n<p>Retatrutide is a triple agonist that targets GLP-1, GIP and glucagon receptors, giving it the broadest receptor profile currently under investigation among incretin peptides. Semaglutide, by contrast, focuses exclusively on GLP-1 receptor activation. This makes Semaglutide the foundational reference molecule for GLP-1 biology, while Retatrutide represents the next generation of multi-receptor metabolic research.<\/p>\n<p><strong>Why is Semaglutide still important when newer peptides exist?<\/strong><\/p>\n<p>Although newer dual- and triple-agonist peptides have generated considerable interest, Semaglutide remains one of the most important compounds in metabolic research because it has the largest and most mature body of published clinical evidence. Many studies evaluating Tirzepatide, Retatrutide and other investigational peptides continue to use Semaglutide as the primary comparator, making it central to understanding how newer incretin therapies differ from established GLP-1 receptor agonism.<\/p>\n<p><strong>What research areas commonly investigate Semaglutide?<\/strong><\/p>\n<p>Published studies have investigated Semaglutide across a broad range of metabolic research areas, including obesity, body-weight regulation, appetite signalling, glucose metabolism, type 2 diabetes, cardiovascular outcomes, fatty liver disease and long-term incretin biology. Its extensive evidence base makes it one of the most frequently referenced peptides in modern metabolic research.<\/p>\n<p><strong>How is Semaglutide supplied?<\/strong><\/p>\n<p>This product is supplied as 10 mg of lyophilised Semaglutide in a sterile research vial. Each batch is accompanied by a Certificate of Analysis (COA), and independent third-party analytical verification is available for selected batches. The product is intended exclusively for laboratory and analytical research.<\/p>\n<p><strong>\u00bfEst\u00e1 este producto destinado al uso humano?<\/strong><\/p>\n<p>No. Semaglutide supplied by LIFE Peptide is provided strictly for research use only. It is not intended for human consumption, diagnosis, treatment or prevention of disease. Any discussion of published clinical studies on this page is included solely to summarise the current scientific literature surrounding the Semaglutide molecule.<\/p>\n<h4><strong>Contexto de investigaci\u00f3n relacionado<\/strong><\/h4>\n<p>Semaglutide belongs to the GLP-1 receptor agonist class within incretin-based metabolic research. For mechanistic comparison with dual and triple agonists, see our <strong><a href=\"http:\/\/example.test\/glp-1-metabolic-research-guide\/\" target=\"_blank\" rel=\"noopener\">Gu\u00eda de investigaci\u00f3n metab\u00f3lica de GLP-1<\/a>.<\/strong><\/p>\n<p>Explorar todos los compuestos en el <a title=\"Categor\u00eda de investigaci\u00f3n metab\u00f3lica.\" href=\"\/es\/product-category\/metabolic-research\/\"><strong>Categor\u00eda de investigaci\u00f3n metab\u00f3lica.<\/strong><\/a><\/p>\n<p>For pathway comparison:<\/p>\n<ul data-start=\"2633\" data-end=\"2702\">\n<li data-start=\"2633\" data-end=\"2671\">\n<p data-start=\"2635\" data-end=\"2671\">Dual agonists: \u00a0<a href=\"http:\/\/example.test\/product\/tirzepatide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Tirzepatide (GLP-1\/GIP)<\/a><\/p>\n<\/li>\n<li data-start=\"2672\" data-end=\"2702\">\n<p data-start=\"2674\" data-end=\"2702\">Triple agonists: <a href=\"http:\/\/example.test\/product\/retatrutide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Retatrutide (GLP-1\/GIP\/glucagon)<\/a><\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>NOTE: <\/strong>This is for educational reference only and does not constitute medical advice.<\/p>\n<p><strong>Disclaimer:<\/strong><br \/>\nEste producto se vende \u00fanicamente para fines de investigaci\u00f3n. No est\u00e1 destinado a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. El comprador asume toda la responsabilidad por su manipulaci\u00f3n y uso adecuados.<\/p>","protected":false},"excerpt":{"rendered":"<p>Semaglutide 10 mg is a research-grade GLP-1 receptor agonist supplied in lyophilised form for laboratory use. As one of the most extensively studied incretin peptides, it has become the benchmark compound for research into appetite regulation, body-weight change, glucose metabolism and cardiometabolic signalling.<\/p>\n<p>||<\/p>\n<p>Pureza \u226599% | Env\u00edos a la UE a partir de 5 \u20ac | Posibilidad de elegir env\u00edo gratuito | Se aceptan pagos con tarjeta<\/p>","protected":false},"featured_media":1236,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[19],"product_tag":[257,254,287,248,253,139,255,247,258,246],"class_list":["post-303","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic-research-peptides","product_tag-appetite-regulation","product_tag-blood-glucose-research","product_tag-buy-semaglutide","product_tag-energy-balance","product_tag-glp-1-agonist","product_tag-glp-1-research","product_tag-incretin-signaling","product_tag-metabolic-peptide","product_tag-obesity-peptide","product_tag-weight-loss-peptide","first","instock","taxable","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product\/303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/comments?post=303"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/media\/1236"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/media?parent=303"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product_brand?post=303"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product_cat?post=303"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product_tag?post=303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}